RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB
CYTB323J12201
Phase 2 small_molecule active
Quick answer
RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB for Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active